Journey Clinical’s Post

View organization page for Journey Clinical, graphic

6,341 followers

“These attributes potentially improve the scalability of ketamine use in the community, due to reduced need for in-clinic monitoring, and would also reduce costs associated with clinic visits.” Writer Anuradha Varanasi recently reported on the findings of a clinical trial testing ketamine tablets as a treatment for treatment-resistant depression. Varanasi notes: “The team observed that while 71% of the patients in the placebo group experienced a relapse of a depressive episode, in the group of patients who took 180 mg of ketamine tablets as prescribed, only 43% of patients reported a relapse.” To learn more about whether Ketamine-Assisted Psychotherapy (KAP) treatment would be a good fit for you, please visit: https://bit.ly/3Laycpw

  • No alternative text description for this image

Thank you for sharing these insightful findings! The potential for ketamine to improve scalability and reduce the need for in-clinic monitoring is indeed a significant advancement in the field of mental health treatment. Together, let's continue to explore and embrace innovative treatments for mental health. 🌟

To view or add a comment, sign in

Explore topics